Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)

NCT06196840 is registered in ClinicalTrials.gov with Innostellar Biotherapeutics Co.,Ltd as lead sponsor.

NCT NCT06196840
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06196840 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
Lead sponsor
Innostellar Biotherapeutics Co.,Ltd
Phase
Phase 2
Overall status
Active, not recruiting
Start date
January 24, 2024
Completion date
October 31, 2029
Enrollment
50 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration